NEWS – CONNECTA Therapeutics

CONNECTA Therapeutics, CRG, Hospital del Mar Research Institute and I3PT receive €2.7 million from the Spanish Ministry of Science and Innovation to begin Phase IIa trials for CTH120 in Fragile X syndrome

February 12, 2024

The Phase IIa study will assess the efficacy of CTH120 as an innovative therapy in adults with FXS, the most common form of inherited intellectual disability without a specific treatment. María Martínez, Jordi Fàbrega, Mara Dierssen, Ana Aldea, Rafael de la Torre and Ana Roche…

CONNECTA Therapeutics begins administration of CTH120 to the first healthy volunteers in Phase I clinical trial

July 20, 2023

Hospital del Mar Research Institute CONNECTA Therapeutics announces that the first healthy volunteers in the Phase I clinical trial of CTH120 have been administered the drug at Hospital del Mar – Hospital del Mar Research Institute in Barcelona. The study is recruiting 68 healthy individuals, both women and men aged between 18 and 55…

Connecta Therapeutics starts clinical trials for its Fragile X syndrome drug

June 06, 2023

This Phase I clinical trial will assess the safety and tolerability of CTH120, which acts as a neuroplasticity modulator. CTH120 has shown very promising results in preclinical studies carried out at Dr Mara Dierssen research lab at the Centre for Genomic Regulation in Barcelona. The…

Connecta Therapeutics receives funding to expand therapeutic indications for its FXS drug CTH120

February 03, 2022

Connecta Therapeutics, a biotechnology company that specialises in the discovery and development of new treatments for unmet central nervous system (CNS) needs, has been granted €247,577 in funding through the Neotec programme, managed by the Spanish Ministry of Science and Innovation Centre for the Development…

Connecta Therapeutics drug for fragile X syndrome receives orphan designation from European Medicines Agency

September 07, 2021

CTH120, designed using artificial intelligence techniques, will start Phase I in 2022. CTH120 designation as orphan drug validates and empowers Connecta Therapeutics's strategy in neurodevelopmental diseases.

Connecta Therapeutics, the CRG and the IMIM join forces to develop an innovative treatment for fragile X syndrome

December 01, 2020

The public-private consortium has obtained a grant of €1.97 million from the Spanish National Innovation Agency. Preclinical studies have shown that the CTH120 molecule can modulate neuroplasticity, the ability of cells of the nervous system to regenerate in response to pathological influences.

Connecta Therapeutics, the CRG and the IMIM receive €1.97 million from the Spanish National Innovation Agency to develop a treatment for fragile X syndrome

December 01, 2020

The public-private consortium has earned this grant through the 2019 “Collaboration Challenges” programme

CONNECTA THERAPEUTICS RAISES €1.7 M TO DEVELOP NEW TREATMENT FOR FRAGILE X SYNDROME

September 26, 2020

Connecta Therapeutics has closed a €1.7million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have fragile X syndrome (FXS). CDTI and the biotechnology company’s founders also participated.